

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-38 (canceled)

39. (new) An isolated polypeptide originating from a malaria erythrocyte membrane protein of the sequence according to SEQ ID NO:1 consisting of an amino-terminal part of said sequence, and wherein said amino-terminal part of said sequence comprises domain DBL-1 and said polypeptide binds to a negatively charged heparin sulfate or sulfate-like molecule.

40. (new) The polypeptide according to claim 39, having about 400-500 amino acids.

41. (new) The polypeptide according to claim 39, having a weight of about 100-300 kDa.

42. (new) A recombinant fusion protein comprising a polypeptide according to claim 39.

43. (new) A pharmaceutical composition, comprising the polypeptide according to claim 39 and a pharmaceutically acceptable carrier.

44. (new) A medicament comprising an isolated polypeptide originating from a malaria erythrocyte membrane protein of the sequence according to SEQ ID NO: 1, wherein said malaria erythrocyte membrane protein of the sequence according to SEQ ID NO:1 consists of an amino-terminal part of said sequence, and wherein said amino-terminal part of the sequence comprises domain DB:-1, said polypeptide binds malaria-infected erythrocytes membrane protein, and wherein said polypeptide binds to a negatively charged heparin sulfate or sulfate-like molecule.

45. (new) The medicament according to claim 44, wherein said medicament is in the form of a vaccine.

46. (new) An isolated polypeptide originating from a malaria erythrocyte membrane protein of the sequence according to SEQ ID NO: 1 consisting of an amino-terminal part of said SEQ ID NO:1, said amino-terminal part of said sequence comprises domain

DBL-1, said polypeptide binds malaria-infected erythrocytes membrane protein, and wherein said polypeptide binds to a negatively charged heparin sulfate or sulfate-like molecule.

47. (new) The polypeptide according to claim 39, wherein said polypeptide has a weight of 280 kDa.

48. (new) A composition, comprising an adjuvant and the polypeptide according to claim 39.

49. (new) An isolated polypeptide comprising domain DBL-1.

50. (new) A composition comprising an isolated polypeptide, said isolated polypeptide comprising domain DBL-1 and wherein said isolated polypeptide binds to a negatively charged heparan sulfate or heparan sulfate-like molecule.

51. (new) An isolated polypeptide comprising domain DBL-1 and wherein said polypeptide has a weight of 48 kDa.